Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management: results of a randomised controlled trial

A. van der Hout; F. Jansen; C. F. van Uden-Kraan; V. M. Coupé; K. Holtmaat; G. A. Nieuwenhuijzen; J. A. Hardillo; R. J.Baatenburg de Jong; N. L. Tiren-Verbeet; D. W. Sommeijer; K. de Heer; C. G. Schaar; R. J.E. Sedee; K. Bosscha; M. W.M. van den Brekel; J. F. Petersen; M. Westerman; J. Honings; R. P. Takes; I. Houtenbos; W. T. van den Broek; R. de Bree; P. Jansen; S. E.J. Eerenstein; C. R. Leemans; J. M. Zijlstra; P. Cuijpers; L. V. van de Poll-Franse; I. M. Verdonck-de Leeuw

doi:10.1007/s11764-020-00912-9

Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management: results of a randomised controlled trial

A. van der Hout, F. Jansen, C. F. van Uden-Kraan, V. M. Coupé, K. Holtmaat, G. A. Nieuwenhuijzen, J. A. Hardillo, R. J.Baatenburg de Jong, N. L. Tiren-Verbeet, D. W. Sommeijer, K. de Heer, C. G. Schaar, R. J.E. Sedee, K. Bosscha, M. W.M. van den Brekel, J. F. Petersen, M. Westerman, J. Honings, R. P. Takes, I. HoutenbosW. T. van den Broek, R. de Bree, P. Jansen, S. E.J. Eerenstein, C. R. Leemans, J. M. Zijlstra, P. Cuijpers, L. V. van de Poll-Franse, I. M. Verdonck-de Leeuw

Maxillofacial Surgery (AMC)

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Purpose: The eHealth self-management application ‘Oncokompas’ was developed to support cancer survivors in monitoring health-related quality of life (HRQOL) and symptoms, and obtaining personalized feedback and options for supportive care. The aim of this study was to assess the cost-utility of Oncokompas compared with care as usual (CAU) among cancer survivors. Methods: Survivors were randomly allocated to the intervention or control group. Direct (non-)medical, indirect non-medical costs, and HRQOL were measured at 3- and 6-month follow-up, using iMTA Medical Consumption and Productivity Costs and the EuroQol-5D questionnaires. Mean cumulative costs and quality-adjusted life-years (QALYs) were compared between both groups. Results: In total, 625 survivors were randomized into intervention (n = 320) or control group (n = 305). Base case analysis showed that incremental costs from a societal perspective were − €163 (95% CI, − 665 to 326), and incremental QALYs were 0.0017 (95% CI, − 0.0121 to 0.0155) in the intervention group compared with those in the control group. The probability that, compared with CAU, Oncokompas is more effective was 60%, less costly 73%, and both more effective and less costly 47%. Sensitivity analyses showed that incremental costs vary between − €40 and €69, and incremental QALYs vary between − 0.0023 and − 0.0057. Conclusion: Oncokompas is likely to be equally effective on utilities, and not more expensive than CAU, and will therefore contribute to sustainable cancer survivorship care in a (cost-)effective manner. Implications for Cancer Survivors: Oncokompas seems to improve HRQOL and reduces the burden of several tumour-specific symptoms, while costs from a societal perspective are similar to CAU.

Original language	English
Pages (from-to)	77-86
Number of pages	10
Journal	Journal of cancer survivorship
Volume	15
Issue number	1
DOIs	https://doi.org/10.1007/s11764-020-00912-9
Publication status	Published - Feb 2021

Funding

IMV-dL has received grants from the Dutch Cancer Society (KWF Kankerbestrijding), Pink Ribbon, the Netherlands Organization for Health Research and Development (ZonMW), the SAG Foundation–Zilveren Kruis Health Care Assurance Company, Danone Ecofund–Nutricia, Red-kite (distributor of eHealth tools), and Bristol-Myers Squibb, during the conduct of this study. CRL has received personal fees for global advisory board participation from MSD, during the conduct of this study. All other authors have no conflicts of interest. This study was funded by the Dutch Cancer Society (KWF Kankerbestrijding) (grant number VU 2014-7202).

Funders	Funder number
Danone Ecofund–Nutricia, Red-kite
Dutch Cancer Society
Netherlands Organization for Health Research and Development
SAG Foundation
Zilveren Kruis Health Care Assurance Company
Bristol-Myers Squibb
ZonMw
KWF Kankerbestrijding	VU 2014-7202

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11764-020-00912-9

Persistent URL (handle)

Persistent link

Cite this

van der Hout, A., Jansen, F., van Uden-Kraan, C. F., Coupé, V. M., Holtmaat, K., Nieuwenhuijzen, G. A., Hardillo, J. A., de Jong, R. J. B., Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J. E., Bosscha, K., van den Brekel, M. W. M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., ... Verdonck-de Leeuw, I. M. (2021). Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management: results of a randomised controlled trial. Journal of cancer survivorship, 15(1), 77-86. https://doi.org/10.1007/s11764-020-00912-9

@article{13a1ab51d7da47a3a8af8ab34d80daac,

title = "Cost-utility of an eHealth application {\textquoteleft}Oncokompas{\textquoteright} that supports cancer survivors in self-management: results of a randomised controlled trial",

abstract = "Purpose: The eHealth self-management application {\textquoteleft}Oncokompas{\textquoteright} was developed to support cancer survivors in monitoring health-related quality of life (HRQOL) and symptoms, and obtaining personalized feedback and options for supportive care. The aim of this study was to assess the cost-utility of Oncokompas compared with care as usual (CAU) among cancer survivors. Methods: Survivors were randomly allocated to the intervention or control group. Direct (non-)medical, indirect non-medical costs, and HRQOL were measured at 3- and 6-month follow-up, using iMTA Medical Consumption and Productivity Costs and the EuroQol-5D questionnaires. Mean cumulative costs and quality-adjusted life-years (QALYs) were compared between both groups. Results: In total, 625 survivors were randomized into intervention (n = 320) or control group (n = 305). Base case analysis showed that incremental costs from a societal perspective were − €163 (95% CI, − 665 to 326), and incremental QALYs were 0.0017 (95% CI, − 0.0121 to 0.0155) in the intervention group compared with those in the control group. The probability that, compared with CAU, Oncokompas is more effective was 60%, less costly 73%, and both more effective and less costly 47%. Sensitivity analyses showed that incremental costs vary between − €40 and €69, and incremental QALYs vary between − 0.0023 and − 0.0057. Conclusion: Oncokompas is likely to be equally effective on utilities, and not more expensive than CAU, and will therefore contribute to sustainable cancer survivorship care in a (cost-)effective manner. Implications for Cancer Survivors: Oncokompas seems to improve HRQOL and reduces the burden of several tumour-specific symptoms, while costs from a societal perspective are similar to CAU.",

author = "{van der Hout}, A. and F. Jansen and {van Uden-Kraan}, {C. F.} and Coup{\'e}, {V. M.} and K. Holtmaat and Nieuwenhuijzen, {G. A.} and Hardillo, {J. A.} and {de Jong}, {R. J.Baatenburg} and Tiren-Verbeet, {N. L.} and Sommeijer, {D. W.} and {de Heer}, K. and Schaar, {C. G.} and Sedee, {R. J.E.} and K. Bosscha and {van den Brekel}, {M. W.M.} and Petersen, {J. F.} and M. Westerman and J. Honings and Takes, {R. P.} and I. Houtenbos and {van den Broek}, {W. T.} and {de Bree}, R. and P. Jansen and Eerenstein, {S. E.J.} and Leemans, {C. R.} and Zijlstra, {J. M.} and P. Cuijpers and {van de Poll-Franse}, {L. V.} and {Verdonck-de Leeuw}, {I. M.}",

year = "2021",

month = feb,

doi = "10.1007/s11764-020-00912-9",

language = "English",

volume = "15",

pages = "77--86",

journal = "Journal of cancer survivorship",

issn = "1932-2259",

publisher = "Springer New York",

number = "1",

}

van der Hout, A, Jansen, F, van Uden-Kraan, CF, Coupé, VM, Holtmaat, K, Nieuwenhuijzen, GA, Hardillo, JA, de Jong, RJB, Tiren-Verbeet, NL, Sommeijer, DW, de Heer, K, Schaar, CG, Sedee, RJE, Bosscha, K, van den Brekel, MWM, Petersen, JF, Westerman, M, Honings, J, Takes, RP, Houtenbos, I, van den Broek, WT, de Bree, R, Jansen, P, Eerenstein, SEJ, Leemans, CR, Zijlstra, JM, Cuijpers, P, van de Poll-Franse, LV & Verdonck-de Leeuw, IM 2021, 'Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management: results of a randomised controlled trial', Journal of cancer survivorship, vol. 15, no. 1, pp. 77-86. https://doi.org/10.1007/s11764-020-00912-9

TY - JOUR

T1 - Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management

T2 - results of a randomised controlled trial

AU - van der Hout, A.

AU - Jansen, F.

AU - van Uden-Kraan, C. F.

AU - Coupé, V. M.

AU - Holtmaat, K.

AU - Nieuwenhuijzen, G. A.

AU - Hardillo, J. A.

AU - de Jong, R. J.Baatenburg

AU - Tiren-Verbeet, N. L.

AU - Sommeijer, D. W.

AU - de Heer, K.

AU - Schaar, C. G.

AU - Sedee, R. J.E.

AU - Bosscha, K.

AU - van den Brekel, M. W.M.

AU - Petersen, J. F.

AU - Westerman, M.

AU - Honings, J.

AU - Takes, R. P.

AU - Houtenbos, I.

AU - van den Broek, W. T.

AU - de Bree, R.

AU - Jansen, P.

AU - Eerenstein, S. E.J.

AU - Leemans, C. R.

AU - Zijlstra, J. M.

AU - Cuijpers, P.

AU - van de Poll-Franse, L. V.

AU - Verdonck-de Leeuw, I. M.

PY - 2021/2

Y1 - 2021/2

N2 - Purpose: The eHealth self-management application ‘Oncokompas’ was developed to support cancer survivors in monitoring health-related quality of life (HRQOL) and symptoms, and obtaining personalized feedback and options for supportive care. The aim of this study was to assess the cost-utility of Oncokompas compared with care as usual (CAU) among cancer survivors. Methods: Survivors were randomly allocated to the intervention or control group. Direct (non-)medical, indirect non-medical costs, and HRQOL were measured at 3- and 6-month follow-up, using iMTA Medical Consumption and Productivity Costs and the EuroQol-5D questionnaires. Mean cumulative costs and quality-adjusted life-years (QALYs) were compared between both groups. Results: In total, 625 survivors were randomized into intervention (n = 320) or control group (n = 305). Base case analysis showed that incremental costs from a societal perspective were − €163 (95% CI, − 665 to 326), and incremental QALYs were 0.0017 (95% CI, − 0.0121 to 0.0155) in the intervention group compared with those in the control group. The probability that, compared with CAU, Oncokompas is more effective was 60%, less costly 73%, and both more effective and less costly 47%. Sensitivity analyses showed that incremental costs vary between − €40 and €69, and incremental QALYs vary between − 0.0023 and − 0.0057. Conclusion: Oncokompas is likely to be equally effective on utilities, and not more expensive than CAU, and will therefore contribute to sustainable cancer survivorship care in a (cost-)effective manner. Implications for Cancer Survivors: Oncokompas seems to improve HRQOL and reduces the burden of several tumour-specific symptoms, while costs from a societal perspective are similar to CAU.

AB - Purpose: The eHealth self-management application ‘Oncokompas’ was developed to support cancer survivors in monitoring health-related quality of life (HRQOL) and symptoms, and obtaining personalized feedback and options for supportive care. The aim of this study was to assess the cost-utility of Oncokompas compared with care as usual (CAU) among cancer survivors. Methods: Survivors were randomly allocated to the intervention or control group. Direct (non-)medical, indirect non-medical costs, and HRQOL were measured at 3- and 6-month follow-up, using iMTA Medical Consumption and Productivity Costs and the EuroQol-5D questionnaires. Mean cumulative costs and quality-adjusted life-years (QALYs) were compared between both groups. Results: In total, 625 survivors were randomized into intervention (n = 320) or control group (n = 305). Base case analysis showed that incremental costs from a societal perspective were − €163 (95% CI, − 665 to 326), and incremental QALYs were 0.0017 (95% CI, − 0.0121 to 0.0155) in the intervention group compared with those in the control group. The probability that, compared with CAU, Oncokompas is more effective was 60%, less costly 73%, and both more effective and less costly 47%. Sensitivity analyses showed that incremental costs vary between − €40 and €69, and incremental QALYs vary between − 0.0023 and − 0.0057. Conclusion: Oncokompas is likely to be equally effective on utilities, and not more expensive than CAU, and will therefore contribute to sustainable cancer survivorship care in a (cost-)effective manner. Implications for Cancer Survivors: Oncokompas seems to improve HRQOL and reduces the burden of several tumour-specific symptoms, while costs from a societal perspective are similar to CAU.

U2 - 10.1007/s11764-020-00912-9

DO - 10.1007/s11764-020-00912-9

M3 - Article

C2 - 32656739

SN - 1932-2259

VL - 15

SP - 77

EP - 86

JO - Journal of cancer survivorship

JF - Journal of cancer survivorship

IS - 1

ER -

Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management: results of a randomised controlled trial

Abstract

Funding

UN SDGs

Access to Document

Persistent URL (handle)

Fingerprint

Cite this